PROBLEMS OF COMPLICATED INTRA-ABDOMINAL INFECTION’S ANTIBACTERIAL TREATMENT IN MULTIDISCIPLINARY HOSPITALS

The objective is to assess the economic efficiency of the current practice of complicated IAI (intra-abdominal infections) treatment with antibiotics compared to the strategy of the therapy with carbapenem without antipseudomonal activity (Ertapanem).

Materials and methods. We analyzed the economic efficiency of the current practice of IAI treatment compared to alternative therapy.

Results. In current practice the cost of treatment of 1 case of complicated IAI is 82771.85 rub compared to 91471.55 rub for alternative strategy. Analysis of the impact on the Russian budget, out of the expected number of IAI cases in the Russian Federation, revealed that the current practice of antibacterial therapy allows saving up to 544166014 rubles. The proceeds allows to treat additionally 6574 patients with IAI.

Conclusions. In real practice the use of antibiotics in complicated IAI treatment was assessed as more beneficial. Nevertheless, there is a lack of necessary data regarding the bacterial resistance in dynamic that could provide more information about the real economic consequences of «collateral damage» due to the current practice of using the antibiotic therapy.

complicated intra-abdominal infection, bacterial resistance, pharmacoeconomic analysis

1. Victor S. Savelyev, Boris R. Gelfand. Russian national recommendation. Abdominal surgical infection. М.2011.P.99. URL: http://ab.rumedo.ru/wpcontent/uploads/2016/pdf/rekomendatcii%20po%20abdominalnoi%20hirurgicheskoi%20infektcii %202011.pdf (In Russ.)

2. Walters DJ, Solomkin JS, Paladino JA. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intraabdominal infections. Pharmacoeconomics 1999;16: 551–61

3. Laxminarayan R, Brown GM. Economics of antibiotic resistance: a theory of optimal use. J Environ Econ Manage 2001;42:183–206

4. Sturkenboom MC, Goettsch WG, Picelli G, et al. Inappropriate initial treatment of secondary intraabdominal infections leads to increased risk of clinical failure and costs. Br J Clin Pharmacol 2005;60:438– 43

5. McGowan JE. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Infect Dis 1983;5:1033–48.

6. Cohen FL, Tartasky D. Microbial resistance to drug therapy: a review. Am J Infect Control 1997;25:51– 64.

7. Hanberger H, Hoffmann M, Lindgren S, et al. High incidence of antibiotic resistance among bacteria in four intensive care units at a university hospital in Sweden. Scand J Infect Dis 1997;29:607– 14.

8. Muder RR, Brennen C, Drenning SD, et al. Multiply antibioticresistant gram-negative bacilli in a longterm-care facility: a case control study of patient risk factors and prior antibiotic use. Infect Control Hosp Epidemiol 1997;18:808–13.

9. Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997–1998. J Antimicrob Chemother 2000;45:183–9.

10. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39:2206–12.

11. Roman S. Kozlov, Alexey V. Golub. Antimicrobial stewardship as a renascence of the «Golden age» of antibiotics. Clinical microbiology and antimicrobial chemotherapy. 2011;13(4):322-34 (In Russ.)

12. Dinubile MJ, Friedland I, Chan CY, et al. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis 2005;24:443–9.

13. Bohnen JMA, Solomkin JS, Dellinger EP, et al. Guidelines for clinical care: anti-infective agents for intraabdominal infection. A Surgical Infection Society policy statement. Arch Surg 1992;127:83–9.

14. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003;37:997–1005. Surgical Infection Society, Infectious Diseases Society of America. Updated Guideline on Diagnosis and Treatment of Intra-abdominal Infections. 2010. Available at: http://www.journals.uchicago.edu/doi/full/10.1086/649554.

15. Sartelli M et al. Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference. World Journal of Emergency Surgery. Available at: https://wjes.biomedcentral.com/articles/10.1186/s13017-017-0132-7

16. Cardoso T, Almeida M, Friedman ND, Aragão I, Costa-Pereira A, Sarmento E, et al. Classification of healthcare-associated infection: a systematic review 10 years after the first proposal. BMC Med. 2014;12:40

17. Sergey V. Sidorenko, Alexey S. Kolbin, Serhey A. Shlyapnikov. Pharmaco-epidemiological study antimicrobial drug usage in multidisciplinary hospitals. Antibiotics and chemotherapy. 5-6;2017 (In Russ.) in publication.

18. Vitaliy V. Omelyanovskiy, Maria V. Avksentyeva, Maria V. Sura, KV Gerasimova, AV Dzanayeva. Recommendation for budget impact analysis among State program to guarantee free to pay medical care. М. 2016. URL: https://rosmedex.ru/wp-content/uploads/2016/12/MR-AVB-23.12.2016.pdf (In Russ.)

19. Maria V. Avksentyeva, BV Gerasimov, Maria V. Sura. Clinico-economical analysis (assessment of medical technology and quality assessment management in medicine). 2004. Newdiamed: М. p.404. (In Russ.)

20. Yuriy B. Belousov. Planning and conducting of clinical trials. 2000. М.: Investigator’s society. P. 579. (In Russ.)

21. Walley T. Haycox А. Boland A. Pharmacoeconomics. 2004: Elsevier Health Sciences. 216

22. Alexey S. Kolbin, Sergey K. Zyryanov, Dmitry Yu. Belousov. Principles of medical technology assessment. Moscow:OKI,2013:42 (In Russ.).

23. Guilbart M et al. Compliance with an empirical antimicrobial protocol improves the outcome of complicated intra-abdominal infections: a prospective observational study. Br J Anaesth. 2016 Jul; 117(1): 66–72.

24. Hoban DJ. Antibiotics and collateral damage. Clin Cornerstone. 2003;Suppl 3:S12-20.

25. Paterson DL. «Collateral damage» from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004 May 15; 38 Suppl 4:S341-5.

26. Roman S. Kozlov. Selection of resistance associated with the use of antimicrobial agents: collateral damage concept. Clinical microbiology and antimicrobial chemotherapy.2010;12;4:284-294. (In Russ.)

27. Arepyeva M., Kolbin A. et al. A mathematical model for predicting the development of bacterial resistance based on the relationship between the level of antimicrobial resistance and the volume of antibiotic consumption. Journal of Global Antimicrobial Resistance. 2017;8:148–156.